Comparative Pharmacology
Head-to-head clinical analysis: COMPAZINE versus DIMENHYDRINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPAZINE versus DIMENHYDRINATE.
COMPAZINE vs DIMENHYDRINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Dimenhydrinate is a histamine H1 antagonist with central anticholinergic activity. It acts by blocking H1 receptors in the brain's vomiting center and inhibiting vestibular stimulation. It also has anticholinergic effects by binding to muscarinic receptors, reducing motion sickness.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
50-100 mg orally or intramuscularly every 4-6 hours as needed; maximum 400 mg per day. For motion sickness, 50-100 mg 30 minutes before travel.
None Documented
None Documented
Clinical Note
moderateDimenhydrinate + Venlafaxine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine."
Clinical Note
moderateDimenhydrinate + Nefazodone
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefazodone."
Clinical Note
moderateDimenhydrinate + Stiripentol
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
Terminal elimination half-life is 5-10 hours in adults, longer in elderly or hepatic impairment (up to 15 hours).
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Primarily renal, with 60-80% of the dose excreted unchanged in urine; minor biliary/fecal elimination accounts for <10%.
Category C
Category C
Antipsychotic (Phenothiazine) / Antiemetic
Antiemetic
Dimenhydrinate + Clomipramine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine."